

Are we prescribing antibiotics wrong?

Outsourcing Clinical Trials Outside of the US

Regulators And Standards Groups Take Steps To Address Emerging Technologies In Biopharma

Two-dimensional liquid chromatography with multiple heart-cutting

Understanding Pharmaceutical Logistics Validation in a Dynamic Environment





Latest White Papers
- Random
Featured News
Latest News
- Title
- Most Views
- Recently Added
- Ordering
- Random



Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the EVEREST Phase ...

UroGen engages in the development and commercialization of solutions for specialty cancers. The ...

Researchers at the Feinstein Institutes for Medical Research have developed a groundbreaking new ...

Obesity affects over a third of the global population and is a major risk factor for numerous ...



Latest Updates
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced ...
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced LEQSELVI™ (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with ...
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the inaugural hotel debut of Tru Niagen® as an in-room ...
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through ...
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be ...
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be impacting as many as 1 in 3 people globally.
C15:0 (pentadecanoic acid), which is naturally present ...
Fresenius announced that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.
These ...
Fresenius announced that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia® ...
Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that will unite leading experts in imaging technology, clinical translation, and ...
Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that will unite leading experts in imaging technology, clinical translation, and data science. One of only a few such institutes in the nation, it aims to drive innovation in ...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with ...
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular ...